|
|
|
by hernews
Posted: Tue., July 8, 2008, 05:09 pm
|
|
|
TUESDAY, July 8 (HealthDay News) -- A genetic test to determine whether a breast cancer patient is likely to respond to treatment with the drug Herceptin (trastuzumab) has been approved by the U.S. Food and Drug Administration.
|
|
|
|
|
|
|
by hernews
Posted: Thu., June 26, 2008, 12:19 pm
|
|
|
THURSDAY, June 26 (HealthDay News) -- Researchers have devised a new breast-imaging technology that appears to be as accurate as MRI scans but several times cheaper.
The technique, called molecular breast imaging (MBI), is still in the early stages of development, the scientists added.
|
|
|
|
|
|
|
by hernews
Posted: Thu., June 26, 2008, 07:25 am
|
|
|
THURSDAY, June 26 (HealthDay News) -- Women with metastatic breast cancer who developed an immune response to an investigational vaccine lived twice as long as those who didn't have an immune response, new research shows.
"If you were an immune responder, you had double the survival of a non-responder," said study author Dr. Susan Domchek, an associate professor of medicine at the University of Pennsylvania.
|
|
|
|
|
|
|
by hernews
Posted: Wed., June 11, 2008, 07:24 am
|
|
|
WEDNESDAY, June 11 (HealthDay News) -- A drug already approved to reduce the risk of breast cancer in high-risk women also seems to cut the risk for other women.
A new analysis finds that those who took raloxifene (Evista) regularly over a number of years were less likely to develop invasive estrogen-receptor (ER) positive breast cancer, compared with women who did not take the drug.
Raloxifene did not, however, cut the risk for noninvasive breast cancer or invasive ER-negative cancers.
|
|
|
|
|
|
|
|
|
